Keytruda® (pembrolizumab) – New indication
December 19, 2018 - Merck announced the FDA approval of Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
Download PDF
